GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Everest Medicines Ltd (HKSE:01952) » Definitions » Valuation Rank

Everest Medicines (HKSE:01952) Valuation Rank


View and export this data going back to 2020. Start your Free Trial

What is Everest Medicines Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Everest Medicines Valuation Rank Related Terms

Thank you for viewing the detailed overview of Everest Medicines's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Everest Medicines Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Everest Medicines Ltd (HKSE:01952) » Definitions » Valuation Rank
Comparable Companies
HKSE:02105 HKSE:06660 HKSE:02315 HKSE:06955 HKSE:09966 HKSE:06855 HKSE:01541 HKSE:02696 HKSE:02480 HKSE:00775 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
6HN:Germany
Address
1168 West Nanjing Road, 16th Floor, CITIC Pacific Plaza, Jing’an District, Shanghai, CHN, 200041
Website
https://www.everestmedicines.com
Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes; Nefecon (TarpeyoTM), EVER001 (previously known as XNW1011), PTX-COVID19-B, Eravacycline (Xerava), EVER206 (also known as SPR206), and others.
Executives
Fu Wei 2307 Founder of a discretionary trust who can infl
Nova Aqua Limited 2201 Interest of corporation controlled by you
C-bridge Joint Value Creation Limited 2201 Interest of corporation controlled by you
Everest Management Holding Co., Ltd. 2101 Beneficial owner
Ra Capital Management, L.p. 2102 Investment manager
Kolchinsky Peter 2305 Beneficiary of a trust
Kolchinsky Anna Inge Leonore Haas 2202 Interest of your spouse
Ra Capital Healthcare Fund, L.p. 2101 Beneficial owner
Ra Capital Healthcare Fund Gp, Llc 2201 Interest of corporation controlled by you
Fu Wei 2307 Founder of a discretionary trust who can infl
Janchor Partners Limited 2102 Investment manager
C-bridge Capital Gp, Ltd. 2501 Other
Vistra Trust (singapore) Pte. Limited 2501 Other
C-bridge Capital Gp Iv, Ltd. 2201 Interest of corporation controlled by you
C-bridge Iv Investment Nine Limited 2101 Beneficial owner